Lycia Therapeutics, Inc. Chief Financial Officer Amy Bachrodt filed a Form 4 on October 26, 2026, disclosing the acquisition of stock options covering 399,746 shares of common stock, with a transaction date of August 11, 2026.

Key Highlights

  • Reporting person: Amy Bachrodt, Chief Financial Officer and 10% Owner of Lycia Therapeutics, Inc. (NASDAQ:LYCA)
  • Security granted: Stock Option (Right to Buy) covering 399,746 shares of common stock
  • Exercise price: $3.70 per share, with a price of derivative security listed as $0
  • Transaction date: August 11, 2026, with a transaction code of A (acquired)
  • Expiration date: August 10, 2036
  • Vesting schedule: 1/4 of the total award vests on June 2, 2027, with an additional 1/48 vesting monthly thereafter, subject to continued service
  • Pre-IPO context: According to the filing, the transaction occurred prior to the issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the issuer's initial public offering

Bachrodt Option Grant Details: Pre-IPO Award Reported Under Rule 16a-2(a)

According to the Form 4 filed with the SEC, Amy Bachrodt, serving as Chief Financial Officer of Lycia Therapeutics, Inc., acquired stock options on August 11, 2026. The options carry an exercise price of $3.70 per share and cover 399,746 shares of common stock, with an expiration date of August 10, 2036. The filing notes the price of the derivative security at acquisition as $0. Following this transaction, Bachrodt beneficially owns 399,746 derivative securities directly.

The filing disclosed that the transaction was reported pursuant to Rule 16a-2(a) because "the transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering." The form was signed by Amy Bachrodt and filed on October 26, 2026.

Regarding the vesting schedule, the filing states that the options vest as to 1/4 of the total award on June 2, 2027, and that "an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date." The ownership form is reported as direct. No non-derivative securities transactions were reported in Table I of this filing.

What Was Disclosed

Amy Bachrodt, CFO of Lycia Therapeutics, Inc. (NASDAQ:LYCA), reported the acquisition of 399,746 stock options at an exercise price of $3.70 per share, transacted on August 11, 2026, and disclosed via Form 4 filed October 26, 2026, under a pre-IPO reporting rule.